Cellectar Q3 Loss Widens to $8M as WM Trial Nears 2027

Cellectar Biosciences (NASDAQ: CLRB) reported a third-quarter 2026 net loss of $8.0 million, or $0.46 per share, on November 10, 2026, wider than the $4.4 million loss a year earlier. Research and development spending rose to roughly $5.4 million from $2.5 million, and the company ended the quarter with $24.6 million in cash and equivalents, which it said funds budgeted operations into the second quarter of 2027.

Context — Why Cellectar's Q3 Matters Now

The quarter's spending increase traces to two programs. Cellectar said the initiation of its Phase 3 confirmatory trial of iopofosine I 131 in Waldenström macroglobulinemia and higher activity in its ongoing Phase 1b trial of CLR 125 in triple-negative breast cancer drove the R&D jump. That is a deliberate shift from a data-generation phase toward registration preparation.

The cash position frames the timeline. At $24.6 million, up from $13.2 million at December 31, 2025, the balance reflects roughly $31.7 million in net proceeds from a May 2026 offering. Cellectar said that balance is adequate into the second quarter of 2027, the same window in which it plans to file for accelerated approval.

Macro conditions for small-cap biotech remain tied to rate expectations, and the report gives no company-specific financing commentary beyond the offering and the runway statement. The company did not disclose the terms of the May 2026 offering.

The catalyst chain runs from data to filing. Updated Phase 2b CLOVER-WaM results presented at the International Workshop for Waldenström Macroglobulinemia, plans for three posters at ASH 2026, and site activation for the confirmatory trial all precede a planned New Drug Application submission in the first half of 2027.

A case study also landed in the quarter: a heavily pretreated diffuse large B-cell lymphoma patient who received four prior lines of therapy achieved a complete response by Day 85 that has held for more than eight years without further anticancer therapy, per the company.

Data — What the Numbers Show

The headline financial figures compare unfavorably year over year. Net loss per share narrowed to $0.46 from $1.41 despite the larger absolute loss, because weighted-average shares outstanding rose to 17.46 million from 3.16 million. General and administrative expenses edged up to roughly $2.7 million from $2.3 million.

Metric	Q3 2026	Q3 2025
Net loss	$8.0M	$4.4M
R&D expense	$5.4M	$2.5M
G&A expense	$2.7M	$2.3M
Net loss per share	$0.46	$1.41
Cash and equivalents	$24.6M	—

The clinical numbers come from a subset of 24 evaluable patients treated immediately after BTK inhibitor therapy. Cellectar reported an overall response rate of 87.5%, a major response rate of 79.2%, median duration of response of 16.0 months, treatment-free survival of 19.1 months, and a clinical benefit rate of 100%. Treatment-emergent adverse events occurred in under 10% of patients, with cytopenias the only Grade 3 or higher events.

The patient mix in that analysis matters. Patients had received a median of three prior lines of therapy, ranging from two to seven, and included TP53 mutations in 17% and MYD88 wild-type disease in 29% — subsets the company said historically show lower response rates and shorter durations of response.

Balance sheet detail: total assets rose to $29.7 million from $15.0 million at year-end 2025, while total liabilities grew to $7.3 million from $5.1 million. Accumulated deficit reached $289.7 million.

Analysis — What It Means for Markets and Tickers

Cellectar sits in the radioisotope and targeted-radiotherapy corner of oncology, where capital intensity is high and timelines are long. The confirmatory trial design — a comparator, randomized controlled study of 100 WM patients per arm with progression-free survival as the primary endpoint — is a large undertaking for a company of this size, and the cost structure reflects that.

The dilution story is the one equity holders will weigh. Shares outstanding rose to 10.04 million from 4.24 million at December 31, 2025, and additional paid-in capital climbed to $312.1 million from $277.1 million. The per-share loss looks better only because the share count roughly doubled.

The clearest counter-argument to the bull case is timing risk. The company's own runway statement extends only into the second quarter of 2027, and the planned NDA submission sits in the first half of 2027. Any slippage in enrollment or filing would compress the gap between cash needs and the next financing.

A second limitation is the evidence base. The 87.5% response rate comes from a Phase 2b subset of 24 patients, not from randomized data. The Phase 3 trial is designed to generate that randomized evidence, which is why its execution carries the program's value.

Positioning around CLRB is event-driven. Investors are effectively underwriting a binary regulatory and clinical calendar rather than near-term revenue, since the company reported no product revenue. Sector peers in radiopharmaceuticals trade on similar catalyst timelines.

Outlook — What to Watch Next

Three scheduled events anchor the next two quarters. Cellectar said it will present three posters at the ASH 2026 annual meeting, including updated 12-month follow-up from CLOVER-WaM, a new analysis on duration of response by prior lines of therapy, and the first detailed design disclosure of the confirmatory Phase 3 trial.

The company also said initial dosimetry and safety data from the dose-escalation Phase 1b trial of CLR 125 in TNBC are expected in the fourth quarter of 2026 at a medical meeting. That is the nearest scheduled readout.

Operationally, the milestones are first patient dosed in the Phase 3 confirmatory trial in the first quarter of 2027 and the NDA submission in the first half of 2027. The Phase 1b dosimetry trial in WM, requested by the FDA, is expected to generate data from 20 to 30 newly diagnosed and relapsed patients.

The report names no price levels or technical thresholds for the stock. The financial variable to watch is the cash balance relative to the filing window.

Frequently Asked Questions

What does Cellectar's Q3 2026 loss mean for retail investors?

The loss widened to $8.0 million from $4.4 million a year earlier, driven by clinical trial costs rather than operational deterioration. The per-share figure improved to $0.46 from $1.41 only because the share count grew from a May 2026 offering. For retail holders, the relevant signal is cash runway into the second quarter of 2027 against a planned first-half 2027 NDA filing.

What happens next for Cellectar Biosciences?

The company said it remains on track to dose the first patient in its Phase 3 confirmatory trial of iopofosine I 131 in the first quarter of 2027 and to submit an NDA seeking accelerated approval in the first half of 2027. Nearer term, it expects initial dosimetry and safety data from the CLR 125 Phase 1b trial in the fourth quarter of 2026 and three poster presentations at ASH 2026.

Why did Cellectar's research and development costs rise?

Cellectar attributed the increase to roughly $5.4 million from $2.5 million primarily to the initiation of the Phase 3 confirmatory trial of iopofosine I 131 in Waldenström macroglobulinemia and increased activity in the ongoing Phase 1b trial of CLR 125 in triple-negative breast cancer. Both programs moved into more expensive execution stages during the quarter, which is a cost pattern typical of late-stage clinical development.

Bottom Line

Cellectar's widening loss buys clinical and regulatory progress, but the runway into mid-2027 leaves little room for delay before the planned NDA filing.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.